Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 4th February 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Equine inhaler receives marketing authorisation
"Treating severe equine asthma can be challenging for veterinarians and horse owners" - Erich Schoett.

Aservo Equihaler® will be available for EU distribution in 2020

A novel equine inhaler set to benefit horses suffering from severe equine asthma has been granted marketing approval by the European Commission.


Marking an industry-first in equine medicine, the Aservo Equihaler® is the culmination of more than a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. It is expected to be available for veterinary surgeons in the EU in 2020.


The inhaler incorporates a unique Soft Mist Technology®, found in the human Respimat® inhaler. This allows the active ingredient - ciclesonide - to be inhaled deep into the lung, thereby reducing the risk of lower airway inflammation.

Designed specifically for horses, the inhaler also features an ergonomic handle, dosing lever for ease of handling and a nostril adaptor that fits inside the nostril of the horse to allow for easy inhalation.

Erich Schoett, global business head of equine for the Boehringer Ingelheim Animal Health Business Unit, said: “Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breathe.


“Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”

Become a member or log in to add this story to your CPD history

Webinar to explore history of KC breed registers

News Story 1
 A free webinar exploring the development of the Kennel Club's registration system and the evolution of closed breed registers has been announced.

Hosted by Dr Alison Skipper, veterinary and research advisor at the Kennel Club, the webinar will delve into the development of the registry and how the changing landscape of scientific knowledge has shaped breeding practices. It will also look at what this means for the future of pedigree dogs.

The session will culminate with a look at The Kennel Club's ongoing and future engagement in this area, with a chance for attendees to put forward their thoughts and questions for discussion.

This event takes place on Microsoft Teams on Tuesday, 10 June at 7pm. To learn more, visit events.teams.microsoft.com  

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.